CURE241220P144000
- 0.00
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
Spotlight on AbbVie: Analyzing the Surge in Options Activity
10 Health Care Stocks With Whale Alerts In Today's Session
How Is The Market Feeling About Thermo Fisher Scientific?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Behind the Scenes of Eli Lilly's Latest Options Trends
Jefferies Financial: Trump's return is bullish for growth stocks, with the top 10 having the greatest upside.
Jefferies financial strategists expect that Trump's re-election as president will encourage investors to continue pursuing growth stocks, suggesting that investors avoid value stocks.
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
The Trump economic team may have internal discord, and the key agenda still needs the "understanding king" to make the final decision!
Analysts state that the Trump team's characterization of the economic policy as 'the opponent team' is almost accurate, and the strong opposition between Besant and Lutnik has been publicly reported.
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
'Bunker' and 'Booster' Stocks in the U.S. – Which Would Perform Better in a Downturn Vs. Upturn?
UnitedHealth Group Analyst Ratings
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
US stocks closed | The three major indices rose together, with Dow Jones and S&P hitting new highs; tariff threats dragged down auto stocks, general motors fell 9%
Waiting for PCE inflation, the Fed's November minutes support gradual rate cuts, temporarily suppressing US bond yields and the dollar while gold rallies. The Dow turns higher at the end of the day, hitting new highs for three consecutive days, while small cap stocks fall from the highest level in six days, with chip stocks down more than 1%, but nvidia rebounds by 0.7%. Tesla reverses its decline, Nio falls by 7.7%, Amgen's weight loss drug once fell by more than 12%, and Dell falls more than 9% after hours.
Judge Denies Abbott Request for Retrial, Lower Damages in $500M Baby Formula Case
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Unpacking the Latest Options Trading Trends in Intuitive Surgical
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.